The new study was by the team of Dr Vidlar from the Department of Urology, University Hospital in the Czech Republic. Lallemand says the data makes PACran the first and only PAC-standardised whole cranberry powder to be backed by two controlled clinical studies.

Julie Rosenborg, product manager for Lallemand Health Ingredients said: "We are pleased to offer the whole cranberry powder with the strongest pool of clinical evidence on the market and are ready to support the development of innovative products addressing the urinary health segment.

"PACran has been built from the ground up to deliver cranberry in support of urinary tract health," said Rahul Shinde, research scientist for Decas Botanical Synergies. "

This is the second clinical trial that has shown positive results for PACran's support for women with urinary health issues. These results build on the extensive library of science we have developed in support of PACran."

Contact: Lallemand Health Ingredients
www.lallemandhi.com